DescriptionChemDiv’s Cardiovascular Library contains 23,000 compounds.
Largest commercially available Cardiovascular small molecules library for phenotypic screening.
Challenges in Drug Discovery for Cardiovascular (CV) Diseases.
1) Cardiovascular diseases are the leading cause of death globally.
2) The highest disease economic burden compared to other diseases, and keeps climbing up in all predictive analysis reports.
3) In the United States 11% of people between 20 and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD.
4) Together CVD resulted in 17.9 million deaths in 2015, up from 12.3 million in 1990.
5) Recent advances in systems biology have led to multiple new cardiovascular drug targets, that will challenge the unmet needs via new cardiovascular drug development.
Targets space includes:
Adenosine receptors, Adrenergic receptors, Angiotensin-converting enzyme, Cholesteryl ester transfer protein, Dopamine receptor, HMG-CoA reductase, MAP kinase, Vasopressin receptor, Purinergic receptor and others.
Publications•Gromo, G. et al. (2014) Cardiovascular Drug Discovery: A Perspective from a Research-Based Pharmaceutical Company. Cold Spring Harb. Perspect. Med. 4, a014092.
•Medicines in Development for Heart Disease and Stroke 2018 Report. https://www.phrma.org/report/medicines-in-development-for-heart-disease-and-stroke-2018-report
•Fordyce et al. (2015) Cardiovascular Drug Development. JACC 65 (15), 1567–1582.
•Stern, C.S.; Lebowitz, J. (2010) Latest drug developments in the field of cardiovascular disease. Int. J. Angiol. 19(3), e100-e105.
•ChEMBL database version ChEMBL24 https://www.ebi.ac.uk/chembl/
•PubChem Substance and Compound databases. https://pubchem.ncbi.nlm.nih.gov/search/index.html
•PubMed databases. https://www.ncbi.nlm.nih.gov/pubmed/
•The Binding Database. http://www.bindingdb.org/bind/index.jsp